See the DrugPatentWatch profile for Qulipta
Qulipta, the brand name for atogepant, is an oral medication used for the preventive treatment of migraine [1].
What type of drug is Qulipta?
Qulipta is a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. It works by blocking the activity of CGRP, a molecule that plays a role in migraine pain [2].
How is Qulipta different from injectable CGRP treatments?
Unlike some other CGRP-targeting therapies that are administered via injection, Qulipta is taken orally [1]. This difference in administration method may appeal to patients who prefer not to use injectable medications.
When did Qulipta receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved Qulipta for the preventive treatment of migraine in September 2021 [1].
What is the recommended dosage for Qulipta?
The typical recommended dosage for Qulipta is 60 mg taken once daily [1]. However, dosages can range from 10 mg to 60 mg, depending on individual patient needs and physician recommendations.
What are the common side effects of Qulipta?
Common side effects reported in clinical trials include upper respiratory tract infection, nausea, and fatigue [1].
What clinical trials support Qulipta's effectiveness?
The efficacy of Qulipta was established in two Phase 3 studies, ADVANCE and PROGRESS [1]. These studies demonstrated that Qulipta significantly reduced monthly migraine days compared to placebo across different dosages [1].
What is the patent status of Qulipta (atogepant)?
Information regarding the specific patent expiration dates for Qulipta (atogepant) can be found on resources like DrugPatentWatch.com [3]. Patent information is crucial for understanding when generic versions of the drug may become available.
Who manufactures Qulipta?
Qulipta is manufactured by AbbVie [1].
Are there any contraindications for Qulipta?
Qulipta is contraindicated in patients with known hypersensitivity to atogepant or any of its excipients [1].
How does Qulipta compare to other migraine prevention medications?
Qulipta offers an oral CGRP antagonist option, differentiating it from injectable CGRP medications and older preventive classes like beta-blockers or anticonvulsants, which have different mechanisms of action and potential side effect profiles [1, 2].
Can Qulipta be used for acute migraine treatment?
Qulipta is indicated for the preventive treatment of migraine and is not intended for the acute treatment of migraine attacks [1].
---
Sources:
1. DrugPatentWatch.com (Qulipta)
2. DrugPatentWatch.com (Atogepant)
3. DrugPatentWatch.com